BioArctic AB's partner, Eisai, has announced that the Department of Health in Hong Kong has approved Leqembi for the treatment of Alzheimer's disease. This treatment should be initiated in patients who are at the mild cognitive impairment or mild dementia stage of the disease, mirroring the population in which clinical trials were conducted. With this approval, Hong Kong joins the US, Japan, China, and South Korea in authorizing Leqembi.
The approval in Hong Kong is founded on data from the extensive global Phase 3 Clarity Alzheimer's disease study. In this study, Leqembi achieved its primary endpoint as well as all key secondary endpoints, demonstrating statistically significant results.
In Hong Kong, 9.3% of individuals aged 70 and above suffer from dementia, a figure that increases to 32% among those aged 85 and older. Of this demographic, 73.5% are reported to have Alzheimer's disease.
